Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05294289 · ClinicalTrials.gov registry record
Health-related Quality of Life, Symptom Severity, and Pain Among Patients With PIK3CA-related Overgrowth Spectrum: A Mixed-methods Observational Study
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 77
- Enrollment target
NCT05294289 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 77 participants.
The verdict
NCT05294289 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 77 participants
- Enrollment target
Study Summary
This was a mixed-methods observational study that incorporated both qualitative interviews and longitudinal quantitative data collection through an online survey (initial, 2 months, and 4 months).
Interventions
- OTHER Alpelisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2022-05-16 |
| Est. Completion | 2024-06-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05294289
The ClinicalTrials.gov registry entry for NCT05294289 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Alpelisib is the first listed.
NCT05294289 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05294289 about?
NCT05294289 is a clinical study titled "Health-related Quality of Life, Symptom Severity, and Pain Among Patients With PIK3CA-related Overgrowth Spectrum: A Mixed-methods Observational Study". This was a mixed-methods observational study that incorporated both qualitative interviews and longitudinal quantitative data collection through an online survey (initial, 2 months, and 4 months).
What is the current status of trial NCT05294289?
This trial is currently completed. The enrollment target is 77 participants. The study started on 2022-05-16. Estimated completion is 2024-06-28.
What interventions are being tested in trial NCT05294289?
The interventions under investigation include: Alpelisib (OTHER).
Who is sponsoring clinical trial NCT05294289?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.